CA3096671C - CRYSTALLINE POLYMORPHIC COMPOSITIONS A2-73 OF MATERIAL AND THEIR METHODS OF USE - Google Patents

CRYSTALLINE POLYMORPHIC COMPOSITIONS A2-73 OF MATERIAL AND THEIR METHODS OF USE

Info

Publication number
CA3096671C
CA3096671C CA3096671A CA3096671A CA3096671C CA 3096671 C CA3096671 C CA 3096671C CA 3096671 A CA3096671 A CA 3096671A CA 3096671 A CA3096671 A CA 3096671A CA 3096671 C CA3096671 C CA 3096671C
Authority
CA
Canada
Prior art keywords
formulation
anavex2
dosage form
freebase
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3096671A
Other languages
English (en)
French (fr)
Other versions
CA3096671A1 (en
Inventor
Christopher U. Missling
Alani Selvey
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Priority to CA3256071A priority Critical patent/CA3256071A1/en
Publication of CA3096671A1 publication Critical patent/CA3096671A1/en
Application granted granted Critical
Publication of CA3096671C publication Critical patent/CA3096671C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
CA3096671A 2018-04-12 2019-04-12 CRYSTALLINE POLYMORPHIC COMPOSITIONS A2-73 OF MATERIAL AND THEIR METHODS OF USE Active CA3096671C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3256071A CA3256071A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656435P 2018-04-12 2018-04-12
US62/656,435 2018-04-12
PCT/US2019/027369 WO2019200345A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3256071A Division CA3256071A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Publications (2)

Publication Number Publication Date
CA3096671A1 CA3096671A1 (en) 2019-10-17
CA3096671C true CA3096671C (en) 2025-09-16

Family

ID=68163817

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3096671A Active CA3096671C (en) 2018-04-12 2019-04-12 CRYSTALLINE POLYMORPHIC COMPOSITIONS A2-73 OF MATERIAL AND THEIR METHODS OF USE
CA3256071A Pending CA3256071A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3256071A Pending CA3256071A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Country Status (7)

Country Link
US (3) US11498908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773531A4 (cg-RX-API-DMAC7.html)
JP (4) JP7532718B2 (cg-RX-API-DMAC7.html)
CN (1) CN112105349A (cg-RX-API-DMAC7.html)
AU (2) AU2019253028B2 (cg-RX-API-DMAC7.html)
CA (2) CA3096671C (cg-RX-API-DMAC7.html)
WO (1) WO2019200345A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
JP2025514292A (ja) * 2022-04-29 2025-05-02 ▲蘇▼州科睿思制▲葯▼有限公司 塩酸ブラルカメシンの結晶形、その調製方法およびその使用
US12018005B1 (en) 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
WO2014159814A1 (en) * 2013-03-13 2014-10-02 Patricia Oliver Formulations and tablets for treatment or prevention of neurological disorders
GR1008233B (el) * 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
AU2016248376B2 (en) * 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
MX388953B (es) * 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
EP4616852A3 (en) * 2015-07-22 2025-10-22 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity
JP6866379B2 (ja) * 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN111315375A (zh) * 2017-06-14 2020-06-19 阿纳韦克斯生命科学公司 用于治疗阿尔茨海默病的anavex2-73
AU2018375667B2 (en) * 2017-11-28 2023-03-02 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法

Also Published As

Publication number Publication date
JP2021521188A (ja) 2021-08-26
AU2024205423B2 (en) 2026-06-25
JP2025131907A (ja) 2025-09-09
US20230142424A1 (en) 2023-05-11
US11498908B2 (en) 2022-11-15
JP7532718B2 (ja) 2024-08-14
EP3773531A4 (en) 2021-06-23
AU2019253028A1 (en) 2020-10-15
CA3256071A1 (en) 2025-10-31
US12180174B2 (en) 2024-12-31
AU2019253028B2 (en) 2024-05-30
AU2024205423A1 (en) 2024-08-22
US20250115566A1 (en) 2025-04-10
JP2024038524A (ja) 2024-03-19
JP7758768B2 (ja) 2025-10-22
EP3773531A1 (en) 2021-02-17
US20210115004A1 (en) 2021-04-22
JP2026004574A (ja) 2026-01-14
CA3096671A1 (en) 2019-10-17
WO2019200345A1 (en) 2019-10-17
CN112105349A (zh) 2020-12-18

Similar Documents

Publication Publication Date Title
US12180174B2 (en) A2-73 crystalline polymorph compositions of matter and methods of use thereof
AU2017213475B2 (en) SecA inhibitors and methods of making and using thereof
CA2898631C (en) Toxic aldehyde related diseases and treatment
CA3043610A1 (en) Crystalline forms of a magl inhibitor
WO2017109041A1 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
EP2753613B1 (en) Derivatives of xanthone compounds
US20230321039A1 (en) N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
EP2415472A1 (en) Solid pharmaceutical composition containing amorphous body of solifenacin
EA019689B1 (ru) Бензолсульфонат 2-[[[2-[(гидроксиацетил)амино]-4-пиридинил]метил]тио]-n-[4-(трифторметокси)фенил]-3-пиридинкарбоксамида, его кристаллы, его полиморфы и способы их получения
EP3042654A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
US20240400528A1 (en) Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph
US9623012B2 (en) Formulation comprising benzothiazolone compound
CN111793032A (zh) 一类吡唑啉酮类化合物及其制备方法和用途
KR101714259B1 (ko) 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물(2)
US9776989B2 (en) Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
KR20190090729A (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
KR20250065331A (ko) 퇴행성 질환에 의해 유발되는 인지 저하를 예방하기 위한 조성물 및 방법
KR20110126132A (ko) 4,6-디클로로-1η-인돌-2-카르복실산 유도체 또는 이의 염을 유효 성분으로서 함유하는 시신경 장애의 예방 또는 치료제
WO2019120111A1 (zh) 二甲双胍盐在治疗脑梗死中的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201008

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240821

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250529

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250529

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250911

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250916